Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

BackBeat CNT is the flagship therapy of Orchestra BioMed Inc. It is a bioelectronic treatment that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS).

The BackBeat CNT system is a bioelectronic treatment that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS). 

News | Hypertension | October 10, 2019

October 10. 2019 — Late-breaking results from its MODERATO II double-blind, randomized study of BackBeat Cardiac...

TCT 2019 Late-breaking Presentations in the main arena. The top interventional cardiology studies of 2019. #TCT #TCT19 #TCT2019
Feature | TCT | October 11, 2019

October 10, 2019 — Here are the Cardiovascular Research Foundation (CRF) 12 late-breaking trials and 16 late-...

Canon Medical Launches Alphenix Encore Plus Program
News | Angiography | October 09, 2019

October 9, 2019 — In the complex and fast-paced world of healthcare, customers face the challenge of staying up-to-...

FDA Grants Breakthrough Device Designation for Valiant Thoracoabdominal Aortic Aneurysm Stent Graft
News | Stent Grafts | October 09, 2019

October 9, 2019 — Medtronic plc announced it has received Breakthrough Device designation from the U.S. Food and...

PQ Bypass Granted IDE Approval to Start TORUS SFA Stent Graft Pivotal Study
News | Stent Grafts | October 08, 2019

October 8, 2019 — PQ Bypass Inc. announced it has received full approval of its...

The life of Afib patient Glynn Crawford was saved three days after being prescribed a Zoll LifeVest wearable defibrillator by his cardiologist Barbara Williams, M.D., at   University Hospitals Ahuja Medical CenterShe identified him as a high-risk for sudden cardiac arrest.

The life of Afib patient Glynn Crawford was saved three days after being prescribed a Zoll LifeVest wearable defibrillator by his cardiologist Barbara Williams, M.D., at   University Hospitals Ahuja Medical CenterShe identified him as a high-risk for sudden cardiac arrest.

Feature | Sudden Cardiac Arrest | October 07, 2019

October 7, 2019 — Glynn Crawford was hospitalized at University...

A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography. Study Finds Sustained Benefit for TAVR vs. SAVR at One Year. #TCT2019 #TCT19

A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography.

News | Heart Valve Technology | October 04, 2019

October 4, 2019 – A new analysis of the PARTNER 3 Trial data found a modest, but significant, improvement in one-...

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019

October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve...

Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent Sapien 3 transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to those who had surgical aortic valve replacement (SAVR). However, TAVR using a transthoracic approach had poorer outcomes compared to SAVR. #TCT2019
News | Heart Valve Technology | October 03, 2019

October 3, 2019 – Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and...

COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019

October 3, 2019 – The three-year results from the...

The Boston Scientiofic Acurate Neo TAVR valve did not meet non-inferiority to the Sapien 3 valve in patients with severe aortic stenosis. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019

October 2, 2019 – The first randomized trial to compare the safety and efficacy of the new Boston Scientific Acurate...

Overlay Init